Intellia Therapeutics Inc. (NASDAQ:NTLA) saw its shares decline roughly 3% on Monday, following an initial increase after the company released positive Phase 3 results for its hereditary angioedema, or HAE, investigational therapy. The results represent the first global Phase 3 data reported for an in vivo gene editing treatment.
The company said its HAELO Phase 3 study of lonvoguran ziclumeran, referred to as lonvo-z, achieved the trial's primary endpoint along with all key secondary endpoints. According to Intellia, a single dose of lonvo-z reduced HAE attack frequency by 87% compared with placebo over a six-month observation window. The mean monthly attack rate in the treatment arm was 0.26, versus 2.10 in the placebo arm.
The randomized study enrolled 80 patients in total. Fifty-two participants received lonvo-z and 28 received placebo. Intellia reported that most individuals treated with lonvo-z remained free from both attacks and from ongoing prophylactic therapy throughout the six-month evaluation period. The company also stated that, as of the data cutoff on February 10, all patients who received lonvo-z were not on long-term prophylaxis therapy.
Intellia said it has initiated a rolling submission of a biologics license application to the U.S. Food and Drug Administration and is planning for a potential U.S. product launch in the first half of 2027, conditional on regulatory approval. The investigational treatment is designed as a one-time outpatient administration that inactivates the KLKB1 gene to durably lower levels of kallikrein and bradykinin.
The company reported favorable safety and tolerability findings from the HAELO study. The most frequently observed treatment-emergent adverse events were infusion-related reactions, headache and fatigue. Intellia noted that all adverse events reported through the data cutoff were classified as mild or moderate in severity, and there were no serious adverse events reported in the lonvo-z treatment group.
Additional clinical results from the HAELO trial are scheduled for presentation at the 2026 European Academy of Allergy and Clinical Immunology Congress in June.
Market reaction and context
Although the clinical data were positive, Intellia shares moved lower after an initial pop in trading. The company emphasized the one-time, outpatient nature of lonvo-z and its mechanism targeting KLKB1 to reduce kallikrein and bradykinin, which the firm links to HAE attack risk.
What to watch next
- Progress of the rolling biologics license application with the U.S. FDA.
- Full HAELO data release and the scheduled presentation at the 2026 European Academy of Allergy and Clinical Immunology Congress.
- Any regulatory feedback that could affect the timing or content of a potential U.S. launch in the first half of 2027.